When.com Web Search

  1. Ads

    related to: new psoriasis study

Search results

  1. Results From The WOW.Com Content Network
  2. Brodalumab - Wikipedia

    en.wikipedia.org/wiki/Brodalumab

    Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. [3] [4] [5]In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.

  3. Tildrakizumab - Wikipedia

    en.wikipedia.org/wiki/Tildrakizumab

    Later on, in 2019 the 3-year study results of continuous treatment with tildrakizumab were published. Given that psoriasis is a chronic disease that requires lifelong treatment, data on long-term maintenance of clinical responses and long-term safety are of special interest. [15]

  4. Guttate psoriasis - Wikipedia

    en.wikipedia.org/wiki/Guttate_psoriasis

    A retrospective cohort study, spanning from 2009 to 2020, also looked into the long-term outcomes of guttate psoriasis. [16] In this study nearly half of the 120 patients with new-onset guttate psoriasis experienced persistent disease, with some transitioning to the psoriasis vulgaris over time.

  5. 3 Drugmakers Developing Revolutionary Psoriasis Treatments

    www.aol.com/2013/09/20/3-drugmakers-developing...

    For premium support please call: 800-290-4726 more ways to reach us

  6. Tapinarof - Wikipedia

    en.wikipedia.org/wiki/Tapinarof

    Tapinarof, also known as benvitimod and sold under the brand name Vtama, is a medication used for the treatment of plaque psoriasis. [1] The medication is applied to the skin. [1] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [2] [3]

  7. New drugs contribute to AbbVie's upbeat 2020 view ... - AOL

    www.aol.com/news/abbvie-leans-treatments...

    AbbVie said it expects 2020 adjusted earnings of $9.61 to $9.71 per share, above analysts' estimates of $9.48. The profit forecast excludes any impact from the pending $63 billion Allergan deal ...

  1. Ads

    related to: new psoriasis study